Zenapax    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎2

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00071838
(ClinicalTrials.gov)
October 30, 200331/10/2003Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisZenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous SystemMultiple Sclerosis, Relapsing-RemittingDrug: DaclizumabNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted18 Years65 YearsAll16Phase 2United States
2NCT00001934
(ClinicalTrials.gov)
September 19993/11/1999Zenapax to Treat Multiple SclerosisEffect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in MS in a Baseline-to-Treatment, Cross-Over, MRI-Controlled Single Center Phase I/II TrialMultiple SclerosisDrug: ZenapaxNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted18 Years65 YearsBoth22Phase 2United States